* Core Laboratories NV CLB.N CLB is expected to show a
rise in
quarterly revenue when it reports results on February 2.
* The Amsterdam Noord-holland-based company is expected to
report
a 7.6% increase in revenue to $122.368 million from $113.75
million a year ago, according to the mean estimate from 5
analysts, based on Refinitiv data.
* Refinitiv's mean analyst estimate for Core Laboratories
NV is
for earnings of 20 cents per share. For the same quarter last
year, the company reported earnings of 18 cents per share.
* The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 5
"hold" and 2 "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Core
Laboratories
NV is $28, about 4.7% above its last closing price
of $26.67.
*
This summary was machine generated February 1 at 00:09 GMT. All
figures in US dollars unless otherwise stated